A synthetic dengue virus antigen elicits enhanced antibody titers when linked to, but not mixed with, Mycobacterium tuberculosis HSP70 domain II

Vaccine

Volumn 24, Issue 22, 2006, Pages 4716-4726

  Kolli, Rajesh ^a   Khanam, Saima ^a   Jain, Monika ^b   Ganju, Lilly ^b   Ram, M Sai ^b   Khanna, Navin ^a   Swaminathan, S ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

^b DEFENCE INSTITUTE OF PHYSIOLOGY AND ALLIED SCIENCES   (India)

Author keywords

Dengue virus; HSP70; Immune response; Immunodominant epitopes; Mycobacterium tuberculosis

Indexed keywords

AMINO ACID; HEAT SHOCK PROTEIN 70; PLASMID VECTOR; RECOMBINANT DENGUE MULTIEPITOPE IMMUNOGLOBULIN G VACCINE; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DENGUE VIRUS; DRUG MIXTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; GENE CONSTRUCT; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

ANIMALS; ANTIBODIES, VIRAL; BACTERIAL PROTEINS; DENGUE VIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; HSP70 HEAT-SHOCK PROTEINS; IMMUNOGLOBULIN G; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 33646832928     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.030     Document Type: Article

References (34)

1. Gubler D.J. Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century. Trends Microbiol 10 (2002) 100-103
2. Gibbons R.V., and Vaughn D.W. Dengue: an escalating problem. Brit Med J 324 (2002) 1563-1566
3. Guzmán M.G., and Kouri G. Dengue: an update. Lancet Infect Dis 2 (2002) 33-42
4. Lindenbach B.D., and Rice C.M. Flaviviridae: the viruses and their replication. In: Knipe D.M., and Howley P.M. (Eds). Field's Virology. 4th ed. (2001), Lippincott Williams & Wilkins, Philadelphia, PA 991-1041
5. Pang T. Vaccines for the prevention of neglected diseases-dengue fever. Curr Opin Biotechnol 14 (2003) 332-336
6. Halstead SB, Heinz FX, Barrett ADT, Roehrig JT. Conference report on Dengue virus: molecular basis of cell entry and pathogenesis, 25-27 June 2003. Vienna, Austria. Vaccine 2005; 23: 849-56.
7. Hombach J, Barrett AD, Cardosa MJ, Deubel V, Guzman M, Kurane I, et al. Meeting report "Review on flavivirus vaccine development: proceedings of a meeting jointly organized by the World Health Organization and the Thai ministry of public health", 26-27 April 2004. Bangkok, Thailand. Vaccine 2005; 23: 2689-95.
8. Rothman A.L. Dengue: defining protective versus pathologic immunity. J Clin Invest 113 (2004) 946-951
9. Halstead S.B., and Deen J. The future of dengue vaccines. Lancet 360 (2002) 1243-1245
10. Bray M., and Lai C.J. Dengue virus premembrane and membrane proteins elicit a protective immune response. Virology 185 (1991) 505-508
11. Fonseca B.A.L., Pincus S., Shope R.E., Paoletti E., and Mason P.W. Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine 12 (1994) 279-285
12. Falconar A.K.I., Young P.R., and Miles M.A. Precise location of sequential dengue virus subcomplex and complex B cell epitopes on the non-structural-1 glycoprotein. Arch Virol 137 (1994) 315-326
13. Garcia G., Vaughn D.W., and Del Angel R.M. Recognition of synthetic oligopeptides from non-structural proteins NS1 and NS3 of dengue-4 virus by sera from dengue virus-infected children. Am J Trop Med Hyg 56 4 (1997) 466-470
14. Huang J.H., Wey J.J., Sun Y.C., Chin C., Chien L.J., and Wu Y.C. Antibody responses to an immunodominant non-structural 1 synthetic peptide in patients with dengue fever and dengue hemorrhagic fever. J Med Virol 57 (1999) 1-8
15. Srivastava P.K., Menoret A., Basu S., Binder R.J., and McQuade K.L. Heat shock proteins come of age: primitive functions acquire new roles in an adaptive world. Immunity 8 (1998) 657-665
16. Srivastava P.K., and Amato R.J. Heat shock proteins: the 'Swiss army knife' vaccines against cancers and infectious agents. Vaccine 19 (2001) 2590-2597
17. Pockley A.G. Heat shock proteins as regulators of the immune response. Lancet 362 (2003) 469-476
18. Robert J. Evolution of heat shock protein and immunity. Dev Comp Immunol 27 (2003) 449-464
19. Zügel U., and Kaufmann S.H.E. Role of heat shock proteins in protection from and pathogenesis of infectious diseases. Clin Microbiol Rev 12 (1999) 19-39
20. Ang D., Liberek K., Skowyra D., Zylicz M., and Georgeopoulos C. Biological role and regulation of the universally conserved heat shock proteins. J Biol Chem 266 (1991) 24233-24236
21. Gething M.J., and Sambrook J. Protein folding in the cell. Nature 355 (1992) 33-45
22. Rico A.I., Del Real G., Soto M., Quijada L., Martinez-A C., Alonso C., et al. Characterization of the immunostimulatory properties of Leishmania infantum HSP70 by fusion to the Escherichia coli maltose-binding protein in normal and nu/nu BALB/c mice. Infect Immun 66 (1998) 347-352
23. Suzue K., Zhou X., Eisen H.N., and Young R.A. Heat shock protein fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci USA 94 (1997) 13146-13151
24. Chen C.H., Wang T.L., Hung C.F., Yang Y., Young R.A., Pardoll D.M., et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 60 (2000) 1035-1042
25. Hauser H., and Chen S.Y. Augmentation of DNA vaccine potency through secretory heat shock protein-mediated antigen targeting. Methods 31 (2003) 225-231
26. Suzue K., and Young R.A. Adjuvant-free HSP70 fusion protein system elicits humoral and cellular responses to HIV-1 p24. J Immunol 156 (1996) 873-879
27. + T cell independent. J Exp Med 191 (2000) 403-408
28. Flaherty K.M., DeLuca-Flaherty C., and McKay D.B. Three-dimensional structure of the ATPase fragment of a 70K heat-shock cognate protein. Nature 346 (1990) 623-628
29. AnandaRao R., Swaminathan S., Fernando S., Jana A.M., and Khanna N. A custom-designed recombinant multiepitope protein as a dengue diagnostic reagent. Protein Exp Purif 41 (2005) 136-147
30. AnandaRao R., Swaminathan S., Fernando S., Jana A.M., and Khanna N. Recombinant multiepitope protein for early detection of dengue infections. Clin Vaccine Immunol 13 (2006) 59-67
31. Jaiswal S., Khanna N., and Swaminathan S. High-level expression and one-step purification of recombinant dengue virus type-2 envelope domain III protein in Escherichia coli. Protein Exp Purif 33 (2004) 80-91
32. Portaro F.C.V., Hayashi M.A.F., de Arauz L.J., Palma M.S., Assakura M.T., Silva C.L., et al. The Mycobacterium leprae HSP65 displays proteolytic activity. Mutagenesis studies indicate that M. leprae hsp65 proteolytic activity is catalytically related to the Hs1VU protease. Biochemistry 41 (2002) 7400-7406
33. Gaofu Q., Dan M., Jie W., Liao Z., Li Z., Roque R.S., et al. Long-lasting specific antibodies against CETP induced by subcutaneous and mucosal administration of a 26-aminoacid CETP epitope carried by heat shock protein 65 kDa in the absence of adjuvants. Vaccine 22 (2004) 3187-3194
34. Navaratnam M., Deshpande M.S., Hariharan M.J., Zatechka Jr. D.S., and Srikumaran S. Heat shock protein-peptide complexes elicit cytotoxic T-lymphocyte and antibody responses specific for bovine herpesvirus 1. Vaccine 19 (2001) 1425-1434